Madrigal Pharmaceuticals Inc. (MDGL) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Madrigal Pharmaceuticals Inc. (MDGL) carries a Roarable Rating of C- (Hold) with 60/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How MDGL Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $958.4M | 44% | -31.3% | -$288.3M | -$190.0M | -31.9% |
| FY 2024 | $180.1M | 96.5% | -276.4% | -$465.9M | -$457.0M | -45% |
| FY 2023 | $958.4M | 0% | -39.7% | -$373.6M | -$324.2M | -9.1% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring MDGL)
- ✓Live walkthrough of MDGL's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
MDGL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MDGL today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MDGL. Explore sector supply chains on /butterfly.
MDGL Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Madrigal Pharmaceuticals Inc. (MDGL)?
In FY 2025 (10-K), MDGL converted $958.4M of revenue into a 44% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).